2. Academic Validation
  3. Ivermectin and moxidectin against soil-transmitted helminth infections

Ivermectin and moxidectin against soil-transmitted helminth infections

  • Trends Parasitol. 2023 Apr;39(4):272-284. doi: 10.1016/j.pt.2023.01.009.
Eveline Hürlimann 1,  Daniela Hofmann 1,  Jennifer Keiser 2
Affiliations

Affiliations

  • 1 Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Allschwil, Switzerland; University of Basel, Basel, Switzerland.
  • 2 Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Allschwil, Switzerland; University of Basel, Basel, Switzerland. Electronic address: jennifer.keiser@swisstph.ch.
PMID: 36804383 DOI: 10.1016/j.pt.2023.01.009
Abstract

Ivermectin and moxidectin, two macrocyclic lactones, are potent antiparasitic drugs currently registered and mainly used against filarial diseases; however, their potential value for improved soil-transmitted helminth (STH) control has been acknowledged. This review provides insights on recent studies evaluating the efficacy of ivermectin and moxidectin as single or coadministered therapy against human soil-transmitted helminthiases (including Strongyloides stercoralis infections) and on pharmacokinetic/pharmacodynamic parameters measured in treated populations. Furthermore, we discuss current gaps for research, highlight advantages - but also existing challenges - for uptake of ivermectin and/or moxidectin treatment schemes into routine STH control in endemic countries.

Keywords

ivermectin; moxidectin; soil-transmitted helminthiasis.

Figures
Products